ClinicalTrials.gg
RecruitingNCT05880537Updated Sep 15, 2026

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

An observational study in End-Stage Renal Disease, sponsored by LifeNet Health. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by LifeNet Health · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
60th of 121
100 · median 100
Started
2023
with 29 others
Observational
121 of 765
13 open now
Primary completion
2028-12
later than 77 of 95 live
Registered
693rd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 60th largest by planned enrollment of the 121 observational ones that give a count, is one of 30 that started in 2023, is one of 121 observational ones, reaches primary completion later than 77 of the 95 other live ones, and was the 693rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,

Read the detailed description

The clinical objective of this prospective, observational, post market registry study, CR-21-005, is to assess the safety and efficacy of a decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery, LifeNet Health, Virginia Beach, VA) in the creation of vascular access for hemodialysis in patients with ESRD.

03

Conditions studied

  • End-Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The registry subject population will consist of male and female research subjects, 18 years of age or older at the time of graft placement, who require vascular access for hemodialysis that the surgeon determines, in their medical judgement, to be a candidate to receive the Nexeon AVX graft. The target study enrollment is 100 subjects. Each subject will be followed for a maximum of two (2) years or 24 months post-graft placement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be male or female, ≥18 years of age at the time of graft placement
  2. Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis
  3. Subject requires dialysis access to start or maintain dialysis treatment and placement of an AV access graft is a viable access option.
  4. Have the ability themselves, or through their legal guardian, to understand the requirements of the study, to provide written /assent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and to agree to abide by the study restrictions and return to the site for the required assessments
  5. Have provided written authorization for use and disclosure of protected health information

Exclusion criteria

Exclusion Criteria:

  1. Be participating in a study of another drug or device
  2. Have a known sensitivity to any of the processing reagents utilized in the manufacture of this product such as antibiotics (Lincomycin, Polymyxin B, Ciprofloxacin, Meropenum, Gentamicin, or Vancomycin) and processing reagents (N-lauroyl sarcosine, Denarase and glycerol/glycerin)
  3. Have a history or evidence of severe cardiac disease, myocardial infarction within 6 months, ventricular arrhythmias, or unstable angina requiring continuing treatment
  4. Have a history or evidence of severe peripheral vascular disease in the upper extremities
  5. Have the inability or be unable or unwilling to follow the study visit schedule
  6. Have the presence of any condition that, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Open Label

    Open Label for subjects with End-Stage Renal Disease

    Other: Nexeon Arterial Venous Allograft

Interventions

  • OtherNexeon Arterial Venous Allograft

    Nexeon AVX allograft for hemodialysis access in end stage renal disease

06

What researchers measure

Primary outcomes

  1. UltraSound evaluation of allograft functional patency.

    Ultrasound proof of vessel patency and blood flow

    Time frame: 24 months

Secondary outcomes

  1. Secondary Endpoint:

    Evaluating the emergent adverse events as it pertains to the hemodialysis access anatomical site

    Time frame: 24 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2028, 66 months after the start.

Of 151 observational studies under Kidney Failure, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
May 30, 2023
StartActual
Jun 6, 2023
Primary completionEst.
Dec 15, 2028
CompletionEst.
Dec 15, 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05880537
Lead sponsor
LifeNet Health
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Jun 6, 2023
Primary completion
Dec 15, 2028 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Kimberly Dorsch
Contact
kimberly_dorsch@lifenethealth.org
757-609-4378
Monique Alston-Epps
Contact
monique_alstonepps@lifenethealth.org
757-713-4657

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion